抑制大脑的谷氨酸糖酶II (GCPII),以增强认知功能
Robyn Wiseman1, Kristin L Bigos2, Amy F T Arnsten3
1Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, United States; Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Advances in pharmacology (San Diego, Calif.)
|February 10, 2025
概括
抑制谷氨酸碳酸酶II (GCPII) 可能通过向N-乙氨基谷氨酸 (NAAG) 途径来改善认知缺陷. 这种方法解决了对增强执行功能和记忆力的治疗方法的未满足需求.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 认知科学 认知科学
背景情况:
- 认知缺陷在各种疾病中显著影响生活质量,治疗选择有限.
- 第二种类型的甲基酸盐受体3 (mGluR3) 在前额叶皮质神经活动中起着至关重要的作用,对认知功能至关重要.
- N-乙酸甲基谷氨酸 (NAAG) 是mGluR3的内源性激动剂,其通过谷氨酸碳酸酶II (GCPII) 的水解与神经炎症有关.
研究的目的:
- 审查临床前和临床证据支持GCPII抑制作为一种认知增强策略.
- 探索药物发现努力,旨在开发用于治疗目的的穿透大脑的GCPII抑制剂.
主要方法:
- 在认知障碍模型中对GCPII抑制进行现有临床前研究的总结.
- 对研究NAAG-GCPII系统与认知功能相关的临床研究的分析.
- 药物发现策略的概述,重点关注GCPII抑制剂的药理动力学和大脑透率的改善.
主要成果:
- 临床前模型表明,GCPII抑制可以改善认知缺陷.
- 临床研究表明,NAAG-GCPII系统与各种患者群体的认知表现之间存在联系.
- 药物发现工作正在推进,为临床转化创造有效的GCPII抑制剂.
结论:
- 抑制GCPII代表了对认知缺陷的有前途的治疗标.
- 进一步开发穿透大脑的GCPII抑制剂对于临床应用至关重要.
- 针对NAAG-GCPII途径提供了一种治疗认知功能障碍的新方法.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:14Antiepileptic Drugs: Glutamate Antagonists
271
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
271
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
01:22Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
310
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
310
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
216
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
216